Summary

Market Size & Trends

The U.S. clinical trial equipment & ancillary solutions market size was estimated at USD 1.05 billion in 2024 and is projected to reach USD 2.06 billion by 2033, growing at a CAGR of 7.83% from 2025 to 2033. The growth is due to the increasing complexity of clinical trial protocols, which has heightened the need for precision in equipment logistics, device calibration, and timely distribution of trial-related supplies. Sponsors are under growing pressure to meet tight regulatory and study timelines, which in turn has increased reliance on third-party providers specializing in ancillary supply chain management, kitting, equipment leasing, and reverse logistics.

The increasing decentralization of clinical trials in the U.S. is a major driver for the demand for equipment and ancillary solutions. Traditional centralized trials are being replaced or supplemented by hybrid and fully decentralized models, which require extensive logistical coordination and specialized equipment deployment at participants’ homes or local sites. This shift has created a need for direct-to-patient (DTP) supply chains, mobile health kits, connected medical devices, and home-use diagnostics that must be compliant with FDA standards. For instance, the rise of remote ECG monitors, wearable biosensors, and digital spirometers has necessitated ancillary providers capable of managing device calibration, patient training, and data integration remotely. The logistical complexity of supporting multiple remote sites and participants requires real-time tracking, automated resupply systems, and robust reverse logistics - all of which are fueling investments into ancillary solution providers offering end-to-end support tailored for decentralized trials.

The surge in precision medicine and complex therapeutic areas such as oncology, neurology, and gene therapy trials is also propelling the growth of the clinical trial equipment & ancillary solutions industry in the U.S. These trials often demand highly specific equipment like infusion pumps for cellular therapies, customized specimen collection kits, and temperature-controlled drug delivery devices. Ancillary providers are expected to handle specialized packaging, pre-conditioning of equipment, and maintenance protocols to preserve the integrity of temperature- and time-sensitive supplies. The increase in protocol complexity - including biomarker assessments, digital endpoints, and longitudinal sampling - has made the standardization and scalability of ancillary services critical. In response, vendors are integrating cloud-based inventory management, automated labeling, and compliance-tracking tools to streamline processes and meet the heightened demands of sponsors and CROs. This alignment with advanced therapeutic trials is expanding the market beyond basic logistics into high-value clinical trial support infrastructure.

U.S. Clinical Trial Equipment & Ancillary Solutions Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. clinical trial equipment & ancillary solutions market report based on type, and phase:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Sourcing
o Procurement
o Equipment
o Ancillaries
o Rental
o Equipment
o Ancillaries
• Supply/Logistics
o Transportation
o Packaging
o Others
• Service
o Calibrations
o Equipment servicing
o Others
• Others
• Phase Outlook (Revenue, USD Million, 2021 - 2033)
• Phase I
• Phase II
• Phase III
• Phase IV

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Clinical Trial Equipment & Ancillary Solutions Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. U.S. Clinical Trial Equipment & Ancillary Solutions Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.2. Market Restraint Analysis
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. U.S. Clinical Trial Equipment & Ancillary Solutions Market: Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
Chapter 4. U.S. Clinical Trial Equipment & Ancillary Solutions Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Clinical Trial Equipment & Ancillary Solutions Market Type Movement Analysis
4.3. U.S. Clinical Trial Equipment & Ancillary Solutions Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Sourcing
4.4.1. Sourcing Market Estimates and Forecasts, 2021 - 2033 (USD million)
4.4.2. Procurement
4.4.2.1. Procurement Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2.2. Equipment
4.4.2.2.1. Equipment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2.3. Ancillaries
4.4.2.3.1. Ancillaries Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Rental
4.4.3.1. Rental Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.2. Equipment
4.4.3.2.1. Equipment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3.3. Ancillaries
4.4.3.3.1. Ancillaries Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Supply/Logistics
4.5.1. Supply/Logistics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. Transportation
4.5.2.1. Transportation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. Packaging
4.5.3.1. Packaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.4. Others
4.5.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Service
4.6.1. Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.2. Calibrations
4.6.2.1. Calibrations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.3. Equipment servicing
4.6.3.1. Equipment Servicing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.4. Others
4.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Others
4.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Clinical Trial Equipment & Ancillary Solutions Market: Phase Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Clinical Trial Equipment & Ancillary Solutions Market Phase Movement Analysis
5.3. U.S. Clinical Trial Equipment & Ancillary Solutions Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)
5.4. Phase I
5.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Phase II
5.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Phase III
5.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Phase IV
5.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Competitive Landscape
6.1. Company Categorization
6.1.1. Market Leaders
6.1.2. Emerging Players
6.2. Company Market Share/Assessment Analysis, 2024
6.3. Company Profiles
6.3.1. Ancillare, LP
6.3.1.1. Company overview
6.3.1.2. Financial performance
6.3.1.3. Service benchmarking
6.3.1.4. Strategic initiatives
6.3.2. Imperial CRS, Inc.
6.3.2.1. Company overview
6.3.2.2. Financial performance
6.3.2.3. Service benchmarking
6.3.2.4. Strategic initiatives
6.3.3. Woodley Equipment Company Ltd.
6.3.3.1. Company overview
6.3.3.2. Financial performance
6.3.3.3. Service benchmarking
6.3.3.4. Strategic initiatives
6.3.4. Thermo Fisher Scientific, Inc.
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Service benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Parexel International (MA) Corporation
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Service benchmarking
6.3.5.4. Strategic initiatives
6.3.6. Emsere (formerly MediCapital Rent)
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Service benchmarking
6.3.6.4. Strategic initiatives
6.3.7. Quipment SAS
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Service benchmarking
6.3.7.4. Strategic initiatives
6.3.8. IRM
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Service benchmarking
6.3.8.4. Strategic initiatives
6.3.9. Marken (UPS-United Parcel Service)
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Service benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Myonex
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Service benchmarking
6.3.10.4. Strategic initiatives
6.3.11. Yourway
6.3.11.1. Company overview
6.3.11.2. Financial performance
6.3.11.3. Service benchmarking
6.3.11.4. Strategic initiatives